Tracy Hampton, PhD
A new tuberculosis vaccine boosts protectiveness of the current bacille-Calmette-Guérin (BCG) vaccine, which becomes less effective over time, suggest preclinical findings from scientists at the Infectious Disease Research Institute in Seattle and Colorado State University in Fort Collins (Bertholet S et al. Sci Transl Med. 2010;2[53]:53ra74).
The new vaccine consists of a single recombinant fusion protein produced from 4 Mycobacterium tuberculosis (Mtb) antigens from Mtb protein families associated with virulence or latency.
The vaccine induced CD4 T helper type 1 cell responses and led to a reduction in the number of bacteria in the lungs of vaccinated mice that were challenged with virulent or multidrug-resistant Mtb strains, prevented the death of guinea pigs that were vaccinated and subsequently challenged with virulent Mtb, and elicited CD4 and CD8 T cell responses in human peripheral blood mononuclear cells from BCG-vaccinated or Mtb -exposed individuals.
http://jama.ama-assn.org/content/304/21/2350.1.extract
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment